Recombinant ADAMTS-13: Goodbye, allergic reactions!

Research output: Contribution to journalComment/debate

Abstract

In this issue of Blood, Scully et al describe very promising results of a phase 1 study of recombinant ADAMTS-13 (rADAMTS-13; a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13) in patients with congenital thrombotic thrombocytopenic purpura (cTTP) that is likely to make these patients’ lives allergy free.1

Original languageEnglish (US)
Pages (from-to)2045-2046
Number of pages2
JournalBlood
Volume130
Issue number19
DOIs
StatePublished - Nov 9 2017

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this